All News
Is High Dose Aspirin Needed in Kawasaki Disease?
Does aspirin add any advantage to intravenous immunoglobulin (IVIG) alone in children with Kawasaki disease (KD)?
Read Article
Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Sponsored by Sanofi
https://t.co/ZDA7lYHsxe https://t.co/zCBmlUBz4y
Dr. John Cush RheumNow ( View Tweet)
Phase 2, DBRPCT of nanobody anti-IL-17, izokibep in 172 Psoriatic arthritis pts, showed higher ACR50 rates for izokibep 80mg vs PBO at wk 16 (52% vs 13%; p=0.0006) w/ 40mg=48%. Other arthritis, psoriasis, enthesitis, dactylitis, QOL outcomes also improved.https://t.co/ZJmZWdxo5Q https://t.co/EMYC1cnsXP
Dr. John Cush RheumNow ( View Tweet)
EMR Messaging Woes (4.11.2025)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on https://t.co/V10S4oVFsv
https://t.co/Q77RZQJj4G https://t.co/VGQpqNmoB7
Dr. John Cush RheumNow ( View Tweet)
AutoAbs & protein signatures evolve as pts go from Preclinical to established RA. Pts vs controls distinguished w/in 5 yrs of Dx best by iCCP3, RFIgA, RFIgM; and 104 proteins differentially expressed & gene analyses showed 21 pathways enriched ≤5 years of Dx. https://t.co/EWwpvrduJz
Dr. John Cush RheumNow ( View Tweet)
Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M3R Abs; 25% high-titer M3R+. Hi titer M3R+ pts had more diffuse Dz (44% vs 23%), GI severity (91% vs 70%), RNPC3+ (18% vs 6%), U1RNP+(21 vs 2%) https://t.co/OmlLpNXRmE
Dr. John Cush RheumNow ( View Tweet)
The IL-17A inhibitor, secukinumab, is in late-stage development forthe treatment of giant cell arteritis and polymyalgia rheumatica. https://t.co/JzzqS7bSjd https://t.co/PNvHdJsKlL
Dr. John Cush RheumNow ( View Tweet)
Should Lupus Nephritis Receive PJP Prophylaxis?
A current review article suggests that the need for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in patients with systemic lupus erythematosus (SLE) and lupus nephritis will need to be individualized based on therapies and https://t.co/zzRIVG0Sq3
Dr. John Cush RheumNow ( View Tweet)
#JIA #biologics and #tsDMARDs: Are all patients getting the same access? MDTs, share your insights on on-label and off-label prescribing and help improve future care.
💬 Take the survey by 15 April: https://t.co/vC2Pv5vmH4 https://t.co/rRM5rH0QQl
Links:
BSR RheumatologyUK ( View Tweet)
🚨 New publication alert!
We review the latest advances in imaging for axial spondyloarthritis—from high-res MRI and synthetic CT to deep learning algorithms improving lesion detection.
🔗 https://t.co/oddjoFOGzM
#AxSpA #AIinMedicine
@XBaraliakos @WalterMaks @krystelaouad https://t.co/VwuUwYL1Xs
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
FDA reports higher rate of allergic/hypersensitivity type reactions w/ certainlots of Immune Globulin Intravenous (IGIV) and Immune Globulin Subcutaneous (IGSC) ; these have voluntarily withdrawn by the manufacturers https://t.co/N73Cc8rfAS https://t.co/OTROyomvv8
Dr. John Cush RheumNow ( View Tweet)
Full read state of the art review of treatments for Axial Spondyloarthritis
Concluding unmet needs:
-Suboptimal Tx Response
- Limited Drug Options
- No Biomarkers
- Extra-Axial Dz
- Non-Inflammatory Pain https://t.co/K3oqRCgTCP https://t.co/IPn09jMFM2
Dr. John Cush RheumNow ( View Tweet)
Pregnancy-Related Deaths in the US
A CDC cross-sectional national study showed an increase in pregnancy-related deaths in the US from 2018 to 2022, with highest rates among American Indian, Alaska Native women, and non-Hispanic Black women.
https://t.co/H1s649GyiL https://t.co/MXnrQrAcrT
Dr. John Cush RheumNow ( View Tweet)
ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain
The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.
https://t.co/B0eWstjN0Z https://t.co/IzSEIeosme
Dr. John Cush RheumNow ( View Tweet)
"Don’t ever let anyone tell you you ain’t strong enough" – Janis Joplin https://t.co/1B1YD5gDLk
Dr. John Cush RheumNow ( View Tweet)
Uveitis Risk with Slow Adalimumab Weaning
Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort analysis indicated. https://t.co/KgQsK6fVnr
Dr. John Cush RheumNow ( View Tweet)
2nd Opinions in Rheumatology
https://t.co/R4CjJHEaL4 https://t.co/0quDwdANyU
Dr. John Cush RheumNow ( View Tweet)
Vamorolone: a New Steroid on the Horizon?
Vamorolone is a potentially new alternative to traditional glucocorticoids for use in inflammatory diseases. It is a dissociated steroidal compound with reduced side effects, and in an animal model of inflammation has shown effective https://t.co/38WTOAuuJy
Dr. John Cush RheumNow ( View Tweet)
Summary of the updated BSR Axial Spondyloarthritis for biological and targeted synthetic DMARD guidelines 2025 @RheumatologyUK #axialspondyloarthritis
Full paper available at:
https://t.co/LytDiHjawi https://t.co/iaHzD1BQRe
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
📢Calling all paediatrics! #BSR25 is almost here - Check out our top paediatric highlights from a packed Annual Conference programme 🔗Read our latest blog now: https://t.co/8uJMiqg2fW https://t.co/PAASNk3ZuF
Links:
BSR RheumatologyUK ( View Tweet)